Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 0.60 |
| ▸ | HTR1A | P08908 | 6/20 | 0.58 |
| ▸ | DRD3 | P35462 | 6/20 | 0.58 |
| ▸ | DRD2 | P14416 | 5/20 | 0.58 |
| ▸ | HTR2B | P41595 | 5/20 | 0.58 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | HRH1 | P35367 | 4/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918899 | 0.95 | HTR7 (0.62) | HTR7HTR1ADRD3DRD2HTR2B | |
| SCHEMBL2168243 | 0.89 | ALDH1A1 (0.50) | HTR7HTR1ADRD3DRD2HTR2B | |
| SCHEMBL5534105 | 0.82 | AKR1C3 (0.45) | HTR7HTR1ADRD3DRD2HTR2B | |
| SCHEMBL5541021 | 0.82 | HTR7 (0.43) | HTR7HTR1ADRD3DRD2HTR2B | |
| SCHEMBL16063012 | 0.82 | SIGMAR1 (0.47) | HTR7DRD3DRD2 | |
| SCHEMBL5023878 | 0.82 | CARM1 (0.48) | HTR7DRD3DRD2SLC6A4HDAC3 | |
| SCHEMBL5535345 | 0.82 | CARM1 (0.48) | HTR7DRD3DRD2SLC6A4 | |
| SCHEMBL3245085 | 0.82 | DRD2 (0.51) | HTR7HTR1ADRD3DRD2HTR2B | |
| SCHEMBL5534030 | 0.82 | HTR7 (0.43) | HTR7HTR1ADRD3DRD2HTR2B | |
| SCHEMBL10231923 | 0.81 | HTR7 (0.42) | HTR7HTR1ADRD3DRD2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1276483-B1 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | BELLUS HEALTH INT LTD (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | claimed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | claimed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | claimed |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2026-05-14 | — | — | US | disclosed |
| EP-4717756-A2 | LIPASE VARIANTS AND DETERGENT COMPOSITIONS | Novozymes A/S (DK) | 2026-04-01 | — | — | EP | disclosed |
| US-12559736-B2 | Lipase variants and polynucleotides encoding same | NOVOZYMES A/S (DK) | 2026-02-24 | — | — | US | disclosed |
| US-12529017-B2 | Detergent composition comprising a lipase | NOVOZYMES A/S (DK) | 2026-01-20 | — | — | US | disclosed |
| US-20250382594-A1 | METHODS OF REDUCING ODOR | NOVOZYMES A/S (DK) | 2025-12-18 | — | — | US | disclosed |
| US-12492387-B2 | Lipase variants and microcapsule compositions comprising such lipase variants | NOVOZYMES A/S (DK) | 2025-12-09 | — | — | US | disclosed |
| EP-1704217-A1 | ORGANIC CATALYST SYSTEM | The Procter and Gamble Company (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005073360-A1 | ORGANIC CATALYST SYSTEM | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050159327-A1 | Organic catalyst system | THE PROCTER & GAMBLE COMPANY | 2005-07-21 | — | — | US | disclosed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | disclosed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | disclosed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | disclosed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559736-B2 | Lipase variants and polynucleotides encoding same | LPL, PNLIP, LIPG | HTR7 4174/4885HTR1A 3773/4885DRD3 2571/4885 |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | HTR7 3823/4885HTR1A 3414/4885DRD3 3595/4885 |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | LIPE, LPL, PNLIP | HTR7 4105/4885HTR1A 4027/4885DRD3 2148/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | HTR7 3823/4885HTR1A 3414/4885DRD3 3595/4885 |
| US-12529017-B2 | Detergent composition comprising a lipase | MGLL, LPL, LIPC | HTR7 3338/4885HTR1A 4577/4885DRD3 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.